Larimar Therapeutics, Inc. (LRMR) Financials

LRMR

FY2025 annual

Revenue Not reported for FY2025

Net Income -$165.7M -105.5% YoY

Free Cash Flow -$113.3M -59.0% YoY

Operating Cash Flow -$113.2M -60.0% YoY

Market Cap $285.7M as of Oct 8, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 2.2x on $127.4M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 4, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LRMR SEC filings page.

This page shows Larimar Therapeutics, Inc. (LRMR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LRMR FY2025 2026-10-04

Larimar operates as a development-stage biotech: research spending drives cash use while financing, not operations, supplies liquidity.

In FY2025, the net loss widened from $80.6M to $165.7M as research spending rose from $73.3M to $154.2M, but operating cash outflow increased less sharply to $113.2M. That widening gap means accounting losses and cash consumption diverged, likely reflecting larger noncash or timing effects rather than every reported loss dollar being paid immediately.

Free cash flow of -$113.3M nearly matched operating cash flow of -$113.2M, leaving only $91K between them. Capital expenditures were immaterial, so the cash requirement came from development operations rather than building a heavy physical asset base.

The current ratio fell from 8.0x to 2.2x, leaving a much smaller short-term asset cushion. The reported debt-to-equity ratio reached 0.9x, while investing and financing inflows outweighed operating cash use, showing that liquidity was replenished externally rather than earned.

Financial Health Signals

Financial health score not available

Larimar Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

Larimar Therapeutics, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Larimar Therapeutics, Inc. reported a net loss of $165.7M while operations used $113.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$34.3M

YoY-23.8%

QoQ-10.4%

Larimar Therapeutics, Inc.'s EBITDA was -$34.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 23.8% from the same quarter a year earlier. Against the prior quarter it is down 10.4%.

Net Income

-$32.8M

YoY-25.2%

QoQ-10.7%

Larimar Therapeutics, Inc. reported -$32.8M in net income in Q2 2026. This represents a decrease of 25.2% from the same quarter a year earlier. Against the prior quarter it is down 10.7%.

Revenue

Not reported for Q2 2026.

EPS (Diluted)

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$92.7M

YoY+350.2%

QoQ-47.9%

5Y CAGR+5.6%

10Y CAGR+16.6%

Larimar Therapeutics, Inc. held $92.7M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

104M

YoY+21.4%

QoQ0.0%

5Y CAGR+42.5%

10Y CAGR+14.3%

Larimar Therapeutics, Inc. had 104M shares outstanding in Q2 2026. This represents an increase of 21.4% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-25.7%

YoY-3.9pp

QoQ-7.0pp

Larimar Therapeutics, Inc.'s ROE was -25.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 3.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 7.0 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$28.0M

YoY+19.8%

QoQ+11.9%

Larimar Therapeutics, Inc. invested $28.0M in research and development in Q2 2026. This represents an increase of 19.8% from the same quarter a year earlier. Against the prior quarter it is up 11.9%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

LRMR Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LRMR quarterly income statement

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0	$0	$0	$0	$0	$0
R&D Expenses	$154.2M+110.5%	$73.3M+164.8%	$27.7M+14.1%	$24.3M-36.8%	$38.4M+22.3%	$31.4M+51.1%	$20.8M-56.6%	$47.9M+17.4%	$40.8M+2.3%	$39.9M-26.9%	$54.6M+99.4%	$27.4M+186.5%	$9.6M-17.2%	$11.5M
SG&A Expenses	$18.3M+3.8%	$17.6M+25.0%	$14.1M+14.8%	$12.3M+1.7%	$12.1M+5.9%	$11.4M+370.2%	$2.4M-81.6%	$13.2M+8.5%	$12.2M-33.5%	$18.3M-4.7%	$19.2M+135.8%	$8.1M+93.0%	$4.2M+87.8%	$2.2M
Operating Income	-$172.5M-89.8%	-$90.9M-117.7%	-$41.8M-14.3%	-$36.5M+27.6%	-$50.5M-17.9%	-$42.8M-84.4%	-$23.2M+62.0%	-$61.1M-15.3%	-$53.0M+9.0%	-$58.2M+21.1%	-$73.8M-107.7%	-$35.5M-157.9%	-$13.8M+0.1%	-$13.8M
EBITDA	-$172.1M-90.1%	-$90.6M-118.5%	-$41.4M-14.5%	-$36.2M+27.8%	-$50.1M-17.6%	-$42.6M-84.3%	-$23.1M+62.0%	-$60.9M-15.2%	-$52.8M+9.0%	-$58.0M+21.3%	-$73.7M-107.6%	-$35.5M-158.0%	-$13.8M+0.1%	-$13.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	$1.8M-7.0%	$1.9M+1050.3%	$165K-68.8%	$529K-34.4%	$806K-7.4%	$870K	N/A	$97K
Income Tax	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	-$165.7M-105.5%	-$80.6M-118.1%	-$36.9M-4.5%	-$35.4M+30.2%	-$50.6M-19.2%	-$42.5M-83.7%	-$23.1M+62.3%	-$61.4M-18.0%	-$52.0M+10.1%	-$57.9M+22.1%	-$74.3M-103.6%	-$36.5M-160.1%	-$14.0M-1.1%	-$13.9M
EPS (Basic)	N/A	-$1.32-57.1%	-$0.84+38.7%	-$1.37+53.6%	-$2.95+17.4%	-$3.57	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	-$1.32-57.1%	-$0.84	-$1.37	-$2.95+17.4%	-$3.57	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	61M+39.5%	44M	26M	17M+44.4%	12M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$28.0M+19.8%	$25.0M-5.7%	N/A	$44.9M+222.8%	$23.4M+18.7%	$26.6M+105.2%	N/A	$13.9M+111.4%
SG&A Expenses	$6.4M+43.6%	$6.1M+31.3%	N/A	$4.6M+5.1%	$4.4M-10.0%	$4.6M+22.2%	N/A	$4.3M+15.7%
Operating Income	-$34.4M-23.6%	-$31.1M+0.2%	N/A	-$49.5M-171.0%	-$27.8M-13.0%	-$31.2M-86.4%	N/A	-$18.3M-76.7%
EBITDA	-$34.3M-23.8%	-$31.1M+0.2%	N/A	-$49.4M-171.6%	-$27.7M-13.0%	-$31.1M-86.7%	N/A	-$18.2M-77.2%
Income Tax	N/A	N/A	N/A	$0	$0	N/A	N/A	$0
Net Income	-$32.8M-25.2%	-$29.6M-1.1%	N/A	-$47.7M-207.8%	-$26.2M-21.1%	-$29.3M-99.8%	N/A	-$15.5M-71.0%
EPS (Basic)	N/A	N/A	N/A	-$0.61-154.2%	-$0.41-20.6%	-$0.46-70.4%	-$0.46-58.6%	-$0.24-14.3%
EPS (Diluted)	N/A	N/A	N/A	-$0.61-154.2%	-$0.41-20.6%	-$0.46-70.4%	-$0.46-58.6%	-$0.24-14.3%
Diluted Shares (Avg)	N/A	N/A	N/A	78M+22.8%	64M+0.4%	64M+19.4%	N/A	64M+45.3%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.

LRMR Balance Sheet

LRMR quarterly balance sheet

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$145.8M-27.2%	$200.2M+108.7%	$95.9M-24.1%	$126.4M+60.7%	$78.7M-24.9%	$104.7M+1912.8%	$5.2M-95.7%	$121.8M+15.4%	$105.5M-19.8%	$131.6M-30.4%	$189.1M+60.9%	$117.5M+208.1%	$38.1M	N/A
Current Assets	$142.0M-27.3%	$195.3M+116.6%	$90.2M-25.3%	$120.7M+67.2%	$72.2M-26.3%	$98.0M+1962.1%	$4.8M-96.1%	$121.3M+15.6%	$104.9M-19.8%	$130.9M-30.4%	$188.1M+60.5%	$117.2M+213.7%	$37.4M	N/A
Cash & Equivalents	$85.4M+157.1%	$33.2M+24.2%	$26.7M-0.3%	$26.8M-61.7%	$70.1M+2.9%	$68.1M+6654.0%	$1.0M-98.0%	$49.3M+21.0%	$40.8M+26.0%	$32.4M-9.1%	$35.6M-38.7%	$58.1M+63.6%	$35.5M+257.5%	$9.9M
Short-Term Investments	$51.4M-65.8%	$150.2M+150.2%	$60.0M-34.5%	$91.6M	$0-100.0%	$24.5M	$0-100.0%	$68.7M+12.2%	$61.3M-36.7%	$96.8M-35.2%	$149.5M+160.6%	$57.4M	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$67.8M+138.5%	$28.4M+99.9%	$14.2M-8.3%	$15.5M+8.8%	$14.3M-4.9%	$15.0M+154.4%	$5.9M-95.0%	$118.8M+335.5%	$27.3M+175.9%	$9.9M-50.5%	$20.0M+52.9%	$13.1M-87.7%	$106.7M	N/A
Current Liabilities	$64.8M+166.0%	$24.4M+156.2%	$9.5M-11.2%	$10.7M+21.0%	$8.8M-1.6%	$9.0M+52.5%	$5.9M-55.7%	$13.3M+82.4%	$7.3M-26.3%	$9.9M-40.2%	$16.5M+139.7%	$6.9M+136.7%	$2.9M	N/A
Non-Current Liabilities	$3.0M-27.0%	$4.1M-13.8%	$4.7M-1.8%	$4.8M-11.3%	$5.4M-9.9%	$6.0M	$0-100.0%	$105.5M+427.7%	$20.0M	$0-100.0%	$3.5M-44.1%	$6.2M-94.0%	$103.8M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$20.0M0.0%	$20.0M+528.3%	$3.2M	N/A	N/A	N/A	N/A
Total Equity	$78.1M-54.6%	$171.8M+110.2%	$81.7M-26.3%	$110.9M+72.2%	$64.4M-28.2%	$89.7M+13023.9%	-$694K-123.8%	$2.9M-96.3%	$78.2M-35.7%	$121.7M-28.0%	$169.1M+61.9%	$104.4M+252.3%	-$68.6M-25.3%	-$54.7M
Retained Earnings	-$434.8M-61.6%	-$269.2M-42.7%	-$188.6M-24.4%	-$151.6M-30.4%	-$116.3M-77.2%	-$65.6M-183.7%	-$23.1M+93.4%	-$350.9M-21.2%	-$289.6M-21.9%	-$237.5M-32.2%	-$179.7M-70.5%	-$105.4M-52.9%	-$68.9M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$165.3M+10.2%	$208.5M+22.5%	$145.8M-27.2%	$187.3M-14.5%	$150.0M-36.8%	$170.2M-31.4%	$200.2M+108.7%	$219.0M+110.7%
Current Assets	$160.7M+10.4%	$205.0M+23.9%	$142.0M-27.3%	$183.2M-14.1%	$145.6M-37.0%	$165.5M-28.3%	$195.3M+116.6%	$213.3M+116.5%
Cash & Equivalents	$92.7M+350.2%	$177.9M+742.2%	$85.4M+157.1%	$90.1M+157.1%	$20.6M-36.3%	$21.1M-80.8%	$33.2M+24.2%	$35.1M-9.4%
Short-Term Investments	$63.6M-46.1%	$22.5M-83.5%	$51.4M-65.8%	$85.3M-49.4%	$117.9M-39.1%	$136.4M+16.4%	$150.2M+150.2%	$168.6M+196.5%
Long-Term Investments	$0	$0	$0	$0	$0	$0-100.0%	$0	$0
Total Liabilities	$37.9M+25.8%	$50.5M+94.9%	$67.8M+138.5%	$48.3M+134.3%	$30.1M+17.0%	$25.9M+49.2%	$28.4M+99.9%	$20.6M+83.5%
Current Liabilities	$34.2M+28.2%	$47.8M+115.8%	$64.8M+166.0%	$45.1M+177.0%	$26.6M+26.0%	$22.1M+72.4%	$24.4M+156.2%	$16.3M+148.3%
Non-Current Liabilities	$3.8M+7.7%	$2.7M-27.8%	$3.0M-27.0%	$3.2M-26.3%	$3.5M-24.3%	$3.8M-16.6%	$4.1M-13.8%	$4.3M-7.4%
Total Equity	$127.4M+6.3%	$158.0M+9.5%	$78.1M-54.6%	$139.0M-29.9%	$119.9M-43.3%	$144.3M-37.5%	$171.8M+110.2%	$198.4M+114.0%
Retained Earnings	-$497.2M-53.2%	-$464.4M-55.6%	-$434.8M-61.6%	-$372.3M-54.9%	-$324.6M-44.4%	-$298.4M-46.9%	-$269.2M-42.7%	-$240.3M-36.9%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

LRMR Cash Flow Statement

LRMR quarterly cash flow statement

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	-$113.2M-60.0%	-$70.8M-111.5%	-$33.5M-21.4%	-$27.6M+34.5%	-$42.1M+0.2%	-$42.2M-85.9%	-$22.7M+55.9%	-$51.5M-17.6%	-$43.8M+15.8%	-$52.0M+12.7%	-$59.6M-110.9%	-$28.2M-88.2%	-$15.0M-10.4%	-$13.6M
Depreciation & Amortization	$350K+10.1%	$318K+2.3%	$311K-2.2%	$318K-2.5%	$326K+110.3%	$155K+98.7%	$78K-70.1%	$261K+38.8%	$188K-11.3%	$212K+202.9%	$70K+337.5%	$16K+33.3%	$12K+9.1%	$11K
Stock-Based Compensation	$7.0M-20.4%	$8.8M+15.5%	$7.6M+15.0%	$6.6M+20.9%	$5.5M+153.3%	$2.2M+1575.2%	$129K-98.7%	$9.6M+16.0%	$8.3M-17.9%	$10.1M+17.8%	$8.6M+452.6%	$1.6M+293.2%	$395K+226.4%	$121K
Capital Expenditures	$91K-82.3%	$515K+214.0%	$164K+64.0%	$100K-70.0%	$333K+437.1%	$62K-25.3%	$83K-23.1%	$108K+96.4%	$55K-91.7%	$660K+10.9%	$595K+925.9%	$58K+241.2%	$17K+750.0%	$2K
Free Cash Flow	-$113.3M-59.0%	-$71.3M-112.0%	-$33.6M-21.5%	-$27.7M+34.8%	-$42.4M-0.4%	-$42.3M-85.5%	-$22.8M+55.8%	-$51.6M-17.7%	-$43.8M+16.7%	-$52.6M+12.5%	-$60.1M-112.5%	-$28.3M-88.4%	-$15.0M-10.5%	-$13.6M
Investing Cash Flow	$100.3M+217.5%	-$85.4M-356.0%	$33.4M+136.7%	-$91.0M-476.3%	$24.2M+41.4%	$17.1M+20690.4%	-$83K+98.8%	-$6.9M-119.3%	$35.6M-30.7%	$51.4M	N/A	N/A	N/A	N/A
Financing Cash Flow	$65.1M-59.8%	$161.9M+539510.0%	$30K-100.0%	$75.3M+278.5%	$19.9M-78.8%	$93.6M+382.5%	$19.4M-71.0%	$66.9M+304.0%	$16.6M+710.0%	-$2.7M	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$44.0M-127.2%	-$44.6M-68.1%	N/A	N/A	-$19.4M-38.6%	-$26.5M-154.9%	-$21.8M-133.5%	-$24.5M-166.8%
Depreciation & Amortization	$62K-28.7%	$64K-27.3%	$87K+13.0%	$88K+18.9%	$87K0.0%	$88K+10.0%	$77K-4.9%	$74K-2.6%
Stock-Based Compensation	$2.1M+17.6%	$2.0M+7.9%	N/A	$1.8M-8.8%	$1.8M-20.6%	$1.8M-13.8%	N/A	$2.0M+7.5%
Capital Expenditures	N/A	N/A	$0-100.0%	$23K-62.9%	$19K	$49K	$179K	$62K
Free Cash Flow	N/A	N/A	N/A	N/A	-$19.4M	-$26.6M	-$22.0M	-$24.6M
Investing Cash Flow	-$40.9M-317.1%	$29.0M+100.7%	N/A	N/A	$18.8M+129.7%	$14.4M+121.1%	$19.2M+830.2%	$27.3M+158.7%
Financing Cash Flow	-$435K	$108.1M	N/A	N/A	N/A	N/A	$36K	$30K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

LRMR Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LRMR quarterly financial ratios

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Return on Equity	-212.2%-165.3pp	-46.9%-1.7pp	-45.2%-13.3pp	-31.9%+46.7pp	-78.6%-31.3pp	-47.4%	N/A	-2106.0%-2039.5pp	-66.5%-19.0pp	-47.5%-3.6pp	-43.9%-9.0pp	-34.9%	N/A	N/A
Return on Assets	-113.6%-73.3pp	-40.3%-1.8pp	-38.5%-10.5pp	-28.0%+36.4pp	-64.4%-23.8pp	-40.6%+404.2pp	-444.8%-394.4pp	-50.4%-1.1pp	-49.3%-5.3pp	-44.0%-4.7pp	-39.3%-8.2pp	-31.0%+5.7pp	-36.8%	N/A
Current Ratio	2.19-5.8x	8.02-1.5x	9.49-1.8x	11.28+3.1x	8.16-2.7x	10.89+10.1x	0.81-8.3x	9.12-5.3x	14.39+1.2x	13.23+1.9x	11.37-5.6x	16.98+4.2x	12.82	N/A
Debt-to-Equity	0.87+0.7x	0.170.0x	0.170.0x	0.14-0.1x	0.22+0.1x	0.17	N/A	6.86+6.6x	0.26+0.2x	0.03-0.1x	0.120.0x	0.13	N/A	N/A
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.00	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-25.7%-3.9pp	-18.7%+1.6pp	N/A	-34.3%-26.5pp	-21.8%-11.6pp	-20.3%-14.0pp	N/A	-7.8%+2.0pp
Return on Assets	-19.8%-2.4pp	-14.2%+3.0pp	N/A	-25.5%-18.4pp	-17.5%-8.3pp	-17.2%-11.3pp	N/A	-7.1%+1.6pp
Current Ratio	4.70-0.8x	4.29-3.2x	2.19-5.8x	4.06-9.0x	5.46-5.5x	7.48-10.5x	8.02-1.5x	13.10-1.9x
Debt-to-Equity	0.300.0x	0.32+0.1x	0.87+0.7x	0.35+0.2x	0.25+0.1x	0.18+0.1x	0.170.0x	0.100.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Larimar Therapeutics, Inc. LRMR	FY2025	N/A	-$165.7M	N/A	$285.7M	—
DiaMedica Therapeutics Inc. DMAC	FY2025	N/A	-$32.8M	N/A	$438.4M	—
Benitec Biopharma Inc. BNTC	FY2026	N/A	-$45.5M	N/A	$313.9M	—
Rocket Pharmaceuticals, Inc. RCKT	FY2025	$0	-$223.1M	N/A	$272.2M	—
Assembly Biosciences, Inc ASMB	FY2025	$72.3M	-$6.1M	-8.5%	$451.6M	61/100

Where Larimar Therapeutics, Inc. Ranks

Frequently Asked Questions

Is Larimar Therapeutics, Inc. profitable?

No, Larimar Therapeutics, Inc. (LRMR) reported a net income of -$165.7M in fiscal year 2025.

What is Larimar Therapeutics, Inc.'s EBITDA?

Larimar Therapeutics, Inc. (LRMR) had EBITDA of -$172.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Larimar Therapeutics, Inc.'s return on equity (ROE)?

Larimar Therapeutics, Inc. (LRMR) has a return on equity of -212.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Larimar Therapeutics, Inc.'s free cash flow?

Larimar Therapeutics, Inc. (LRMR) recorded an outflow of $113.3M in free cash flow during fiscal year 2025. This represents a -59.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Larimar Therapeutics, Inc.'s operating cash flow?

Larimar Therapeutics, Inc. (LRMR) recorded an outflow of $113.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Larimar Therapeutics, Inc.'s total assets?

Larimar Therapeutics, Inc. (LRMR) had $145.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Larimar Therapeutics, Inc.'s capital expenditures?

Larimar Therapeutics, Inc. (LRMR) invested $91K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Larimar Therapeutics, Inc. spend on research and development?

Larimar Therapeutics, Inc. (LRMR) invested $154.2M in research and development during fiscal year 2025.

How many shares does Larimar Therapeutics, Inc. have outstanding?

Larimar Therapeutics, Inc. (LRMR) had 104M shares outstanding as of fiscal year 2025.

What is Larimar Therapeutics, Inc.'s current ratio?

Larimar Therapeutics, Inc. (LRMR) had a current ratio of 2.19 as of fiscal year 2025, which is generally considered healthy.

What is Larimar Therapeutics, Inc.'s debt-to-equity ratio?

Larimar Therapeutics, Inc. (LRMR) had a debt-to-equity ratio of 0.87 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Larimar Therapeutics, Inc.'s return on assets (ROA)?

Larimar Therapeutics, Inc. (LRMR) had a return on assets of -113.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Larimar Therapeutics, Inc.'s P/E ratio?

Larimar Therapeutics, Inc. (LRMR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $285.7M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Larimar Therapeutics, Inc.'s price-to-sales ratio?

Larimar Therapeutics, Inc. (LRMR) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $285.7M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Larimar Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Larimar Therapeutics, Inc. (LRMR) held $136.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $113.2M over that year. Dividing the one by the other, the reported balance equals about 15 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Larimar Therapeutics, Inc.'s Piotroski F-Score?

Larimar Therapeutics, Inc. (LRMR) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Larimar Therapeutics, Inc.'s earnings high quality?

Larimar Therapeutics, Inc. (LRMR) reported a net loss of $165.7M while operations used $113.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.